United Therapeutics Corporation Financials

Market Capitalization $13.32 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	11.77
Forward PE	10.59
Price to Sales TTM	$4.45
Price to Book MRQ	$1.95
Enterprise to Revenue	3.29
Enterprise to EBITDA	6.33

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	40.44%
Operating Margin	48.31%
Return on Assets TTM	12.97%
Return on Equity TTM	19.94%

Income Statement

Revenue TTM	$2,994,099,968
Revenue per Share TTM	$67.02
Quarterly Revenue Growth	17.20%
Gross Profit TTM	$2,664,800,000
EBITDA	$1,748,000,000
Net Income to Common TTM	$1,210,700,032
Diluted EPS TTM	$25.09
Quarterly Earnings Growth YoY	5.10%

Balance Sheet

Total Cash MRQ	$3,321,299,968
Total Cash per Share MRQ	$73.63
Total Debt MRQ	$
Total Debt to Equity MRQ	2.94
Current Ratio MRQ	5.46
Book Value per Share MRQ	$151.02

Cash Flow

Operating Cash Flow TTM	$1,411,800,064
Levered Free Cash Flow TTM	$828,787,520

UTHR Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	44,831,306
Float Shares	41,594,170
Avg 10 Volume	559,450
Avg 30 Volume	None
Shares Short	1,614,964
Short Ratio	2.46
Short % of Shares	4.70%
% Held by Insiders	1.75%
% Held by Institutions	101.25%

Stock Price Summary

Beta	0.58
Fifty Two Week Low	$266.98
Fifty Two Week High	$417.82
Fifty Two Week Change	-6.82%
Day 50 MA	$300.98
Day 200 MA	$337.13

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2009-09-23